Fig. 1From: Low-dose nivolumab in advanced hepatocellular carcinomaKaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) in patients with advanced hepatocellular carcinoma who received low-dose nivolumab. A PFS and (B) OSBack to article page